Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.
Jonathan L. Kaufman, MD: The 3 IMiDs, or immunomodulatory drugs, we have approved—thalidomide, lenalidomide, and pomalidomide—are core parts of treatment for both newly diagnosed patients, as well as relapsed and refractory patients. Most, if not all, regimens in the newly diagnosed setting, whether it’s part of a 3- or 4-drug therapy, will contain the most commonly prescribed IMiD in the United States, which is lenalidomide. In addition, lenalidomide is approved and routinely used as maintenance therapy, both after transplant and after nontransplant-based therapies. In the relapsed setting, there is also significant use of IMiDs, and whether we use lenalidomide or pomalidomide is dependent on whether the patient is refractory to lenalidomide. I consider those patients who are progressing on maintenance lenalidomide to be refractory to lenalidomide. In the second-line setting, we’ll often use the next-generation IMiD or a more potent IMiD, pomalidomide, in combination in those patients who are lenalidomide refractory. In the relapsed setting, in contrast to the upfront setting, it’s more common to have triplet therapies that don’t include an IMiD, like a monoclonal antibody plus a proteasome inhibitor with dexamethasone. That is a common second-line therapy that doesn’t include an IMiD, but if an IMiD wasn’t used in the second line, it would certainly be used in the third-line setting.
Thalidomide was the first IMiD that was used in the United States. Thalidomide has a significant amount of nonhematologic toxicity—fatigue, constipation, neuropathy—such that it makes it a very difficult drug to give patients, especially in combination with other drugs that can cause neuropathy, as well as a hard drug to give for a long period of time. Outside of the United States, because of cost restraints, it is much more common to use thalidomide-based regimens than lenalidomide-based regimens. Lenalidomide, while it has its own toxicities, is much better tolerated than thalidomide, particularly in terms of neuropathy and fatigue.
This transcript has been edited for clarity.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More